Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant

Carlos Solano, Monica Slavin, Alissa J. Shaul, David I. Marks, Catherine Cordonnier, Oliver A. Cornely, Antonio Pagliuca, Lael Cragin, Isidro Jarque, Carolina Garcia-Vidal, Sonja Sorensen, David J. Vanness, Claudie Charbonneau, Jon Andoni Barrueta, Carmen Peral, Marina De Salas-Cansado, Eric J. Bow

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. Generic itraconazole was the least costly AFP (€162) relative to fluconazole (€500), posaconazole oral suspension (€8628) or voriconazole (€6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough IFIs (36 vs 60); thus, the model predicted fewer deaths from breakthrough IFI for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with other licensed antifungal treatment and IFI treatment in a cohort of 1000. Voriconazole resulted in cost savings of €4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost-effective. As primary AFP in alloHSCT patients 180 days posttransplant, voriconazole was more likely to be cost-effective than posaconazole regarding cost per additional IFI and additional death avoided.

Original languageEnglish (US)
Pages (from-to)79-88
Number of pages10
JournalMycoses
Volume60
Issue number2
DOIs
StatePublished - Feb 1 2017

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant'. Together they form a unique fingerprint.

  • Cite this

    Solano, C., Slavin, M., Shaul, A. J., Marks, D. I., Cordonnier, C., Cornely, O. A., Pagliuca, A., Cragin, L., Jarque, I., Garcia-Vidal, C., Sorensen, S., Vanness, D. J., Charbonneau, C., Barrueta, J. A., Peral, C., De Salas-Cansado, M., & Bow, E. J. (2017). Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses, 60(2), 79-88. https://doi.org/10.1111/myc.12552